Jazz Pharmaceuticals registers two CBD-based epilepsy trials, both not yet recruiting
New Phase 2/3 and Phase 3 studies target juvenile myoclonic epilepsy and developmental and epileptic encephalopathy with cannabidiol-based treatments.
Jazz Pharmaceuticals posted two new epilepsy trial registrations this week, both listed as not yet recruiting.
- A Phase 2/3 study (NCT07723963) will test JZP926 capsule as an add-on therapy for Juvenile Myoclonic Epilepsy in participants aged 10 and older. The trial will assess the efficacy of JZP926 capsule as an adjunctive treatment in reducing the frequency of myoclonic seizure days when compared with placebo, as well as the effect of JZP926 capsule on non-seizure endpoints.1 Enrollment: 260 participants (estimated)1, with an estimated start date of 2026-09-181.
- A Phase 3 study (NCT07723976) will evaluate Cannabidiol Oral Solution, called CBD-OS or JZP926-OS, in participants aged 1 and older with Developmental and Epileptic Encephalopathy (DEE). The primary objective of the 6-week Double-blind Treatment Period of the study is to assess the efficacy of CBD-OS in reducing the frequency of countable motor seizures compared with placebo in participants with DEE.2 Enrollment: 120 participants (estimated)2, with an estimated start date of 2026-10-302, and a collaborator, Jazz Pharmaceuticals Research UK Limited2.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.